GlassScriptPhysician profile
Toni Lea Boyko
NPI 1467966440
$12,356.81
in general payments reported to CMS, 2019-2025
52 companies · $4,762 in 2025
The $4,762 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,189 · 2024: $4,407 · 2025: $4,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,356.31 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,827.09 | 2023-2025 | |
| Pfizer INC. | $1,198.83 | 2023-2025 | |
| Ucb, INC. | $1,043.00 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Tg Therapeutics, INC. | $1,025.89 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $700.60 | 2023-2025 | |
| Emd Serono, INC. | $464.26 | 2023-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $438.05 | 2023-2025 | Xcopri |
| Lundbeck LLC | $376.08 | 2023-2025 | Vyepti, Rexulti |
| Biogen, INC. | $374.37 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Alexion Pharmaceuticals, INC. | $345.34 | 2023-2025 | Ultomiris |
| Argenx US, INC. | $333.68 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $279.66 | 2023-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $258.02 | 2023-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $246.38 | 2023-2024 | Gocovri, Gocovri |
| Amgen INC. | $230.41 | 2023-2025 | Uplizna, Aimovig |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $218.92 | 2024-2025 | Infinity |
| Neurelis, INC. | $195.83 | 2023-2025 | Valtoco |
| Genentech USA, INC. | $186.08 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Lilly USA, LLC | $177.30 | 2023-2025 | Amyvid, Reyvow, Emgality |
| Amneal Pharmaceuticals LLC | $171.84 | 2023-2025 | Rytary, Crexont, Lyvispah |
| Celgene Corporation | $149.55 | 2023-2025 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $144.01 | 2024-2025 | Wainua |
| Mallinckrodt Hospital Products INC. | $139.92 | 2023-2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $131.71 | 2023-2025 | Firdapse |
| Eisai INC. | $130.78 | 2023-2025 | |
| Tanabe Pharma America, INC. | $122.34 | 2023-2025 | Radicava |
| Alnylam Pharmaceuticals INC. | $112.27 | 2023-2024 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $109.21 | 2024-2025 | Rexulti |
| Cycle Pharmaceuticals INC | $107.45 | 2025 | Tascenso Odt, Bafiertam |
| Genzyme Corporation | $99.23 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $95.75 | 2023-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $92.85 | 2023-2024 | |
| Merz Pharmaceuticals, LLC | $83.11 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Ani Pharmaceuticals, INC. | $75.78 | 2025 | Purified Cortrophin Gel |
| Impel Pharmaceuticals INC. | $66.89 | 2023 | Trudhesa |
| Vanda Pharmaceuticals INC. | $58.70 | 2024-2025 | Ponvory |
| Janssen Biotech, INC. | $57.72 | 2025 | |
| Harmony Biosciences LLC | $56.35 | 2024 | |
| Csl Behring | $54.58 | 2024-2025 | Hizentra |
| Medtronic, INC. | $47.19 | 2024-2025 | Percept PC Brainsense |
| Kyowa Kirin, INC. | $43.91 | 2023-2024 | Nourianz |
| Livanova USA, INC. | $40.53 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Inspire Medical Systems, INC. | $34.74 | 2024 | Inspire |
| Avion Pharmaceuticals | $33.60 | 2023 | Dhivy |
| Boston Scientific Corporation | $32.06 | 2024-2025 | General - Dbs |
| Sumitomo Pharma America, INC. | $23.51 | 2023 | Aptiom |
| Springworks Therapeutics, INC. | $23.15 | 2025 | Gomekli |
| Amylyx Pharmaceuticals, INC. | $21.55 | 2023 | Relyvrio |
| Horizon Therapeutics Plc | $21.49 | 2023 | Uplizna |
| Axsome Therapeutics, INC. | $21.02 | 2025 | Symbravo |
| Octapharma USA, INC. | $17.13 | 2023 | Panzyga |
| Grifols USA, LLC | $17.10 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Boyko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.